ARCA biopharma, Inc. ABIO · Stock Open ARCA biopharma, Inc. in new tab
ARCA biopharma, Inc. Analysis (ABIO)
Is ARCA biopharma, Inc. a good investment? ARCA biopharma, Inc. (ABIO) is currently trading at 28.80 USD.
For income investors, ARCA biopharma, Inc. pays a dividend yield of 5.60%.
Investor FAQ
Does ARCA biopharma, Inc. pay a dividend?
Yes, it pays an annual dividend of 1.61 USD (5.60% yield).
What asset class is ARCA biopharma, Inc.?
ARCA biopharma, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
| Year | Total Dividends |
|---|---|
| ▸2024 |
0.13 USD
|
| Aug. 29, 2024 | 0.1344 |
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 23, 2004 | 0.33 |
| Jan. 28, 2009 | 1:20 |
| March 5, 2013 | 0.17 |
| Sept. 4, 2015 | 0.14 |
| April 4, 2019 | 0.06 |
| Sept. 3, 2024 | 0.08 |
Community Discussion